[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337042-105":59,"doc-detail-337042-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","efficacy-safety-and-differential-outcomes-of-immune-chemotherapy-with-gemcitabine-cisplatin-and-durvalumab-in-patients-with-biliary-tract-cancers-a-multicenter-real-world-cohort","Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort","","Combined immune-chemotherapy using gemcitabine, cisplatin, and durvalumab (GCD) is evaluated for biliary tract cancers (BTC), motivated by TOPAZ-1 results. A German multicenter retrospective analysis included BTC patients treated with GCD across 9 centers, assessing baseline clinicopathological features, overall survival, response rate, and adverse events. Prognostic effects were tested using Kaplan–Meier and Cox regression. Results covered 165 patients from 2021–2024, with subgroup differences and safety outcomes summarized.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-safety-and-differential-outcomes-of-immune-chemotherapy-with-gemcitabine-cisplatin-and-durvalumab-in-patients-with-biliary-tract-cancers-a-multicenter-real-world-cohort/337042/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-safety-and-differential-outcomes-of-immune-chemotherapy-with-gemcitabine-cisplatin-and-durvalumab-in-patients-with-biliary-tract-cancers-a-multicenter-real-world-cohort/337042.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment regimen was assessed for biliary tract cancer in this study?","Question",{"text":112,"@type":113},"The study evaluated immune-chemotherapy combining gemcitabine, cisplatin, and the PD-L1 inhibitor durvalumab (GCD).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were efficacy and safety outcomes analyzed?",{"text":117,"@type":113},"Patients treated with GCD from 9 German centers were included, with overall survival, response rate, and adverse events analyzed retrospectively using Kaplan–Meier analyses and Cox regression.",{"name":119,"@type":110,"acceptedAnswer":120},"What patient-related factors were associated with overall survival?",{"text":121,"@type":113},"Univariate analysis linked overall survival with age ≥70, ECOG performance status ≥1, status post cholecystectomy, gall bladder cancer status, and higher baseline CRP; GB-CA and ECOG PS ≥1 remained independent in multivariable Cox regression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337042,1790186492,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","DOI: 10. 1002/ueg2.12656  \nORIGINAL ARTICLE  \nEfficacy, safety and differential outcomes of immune‐ chemotherapy with gemcitabine, cisplatin and durvalumab inpatients with biliary tract cancers: A multicenter real world cohort  \nKatharina Mitzlaff1 | Martha M. Kirstein1 | Christian Müller2 |  \nMarino Venerito2  | Alexander Olkus3 | Michael T. Dill3,4,5 | Arndt Weinmann6 | Lorenz Kocheise7  | Alina Busch8 | Kornelius Schulze7 | Gabriel Allo9  | Dirk‐Thomas Waldschmidt9 | Maryam Barsch10  | Bertram Bengsch10 |  \nMichael Quante10 | Maria A. Gonzalez‐Carmona11 | Vera Himmelsbach12 | Fabian Finkelmeier12  | Roman Kloeckner13 | Peter Schirmacher14 | Jens U. Marquardt1  | Carolin Zimpel1   \nCorrespondence  \nCarolin Zimpel, Department of Medicine I, University of Lübeck, UKSH—Campus Lübeck, Ratzeburger Allee 160, Lübeck 23538, Germany.  \nEmail: [carolin.zimpel@uksh.de](carolin.zimpel@uksh.de)  \nAbstract  \nBackground: Combined Immuno‐chemotherapy consisting of gemcitabine, cisplatin and the programmed death‐ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on positive results of the TOPAZ‐1 study.  \nObjective: We here evaluated the efficacy and safety of GCD for BTC in a German multicenter real‐world patient cohort.  \nMethods: Patients with BTC treated with GCD from 9 German centers were included. Clinicopathological baseline parameters, overall survival (OS), response rate and adverse events (AEs) were retrospectively analyzed. The prognostic impact was determined by Kaplan–Meier analyses and Cox regression models.  \nResults: A total of 165 patients treated with GCD between 2021 and 2024 were included in the study. Median OS and median progression‐free survival were 14 months (95% CI 10.3–17. 7) and 8 months (95% CI 6.8–9. 2), respectively. The best overall response rate was 28. 5% and disease control rate was 65. 5%. While extrahepatic and intrahepatic BTC showed similar outcomes, mOS was significantly shorter in patients with gall bladder cancer (GB‐CA) with 9 months (95% CI 5.5– 12.4; p = 0.02). In univariate analyses age ≥70 years, Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥1, status post cholecystectomy, GB‐CA and high baseline CRP values were significantly associated with OS. ECOG PS ≥ 1 and  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(s). United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.  \n1230 - United European Gastroenterol J. 2024;12:1230–1242. wi[leyonlinelibrary.com/journal/ueg2](leyonlinelibrary.com/journal/ueg2)  \nGB‐CA remained independent prognostic factors for OS in multivariable cox regression analysis. AEs have been reported in 130 patients (78.8%), including 149 grade 3–4 AEs (25.5%). One patient died of severe infectious pneumonia. Immune‐ related (ir)AEs occurred in 17 patients (10.3%), including 9 grade 3–4 irAEs (2.2%), which led to treatment interruption in 4 patients.  \nConclusions: Immuno‐chemotherapy in patients with BTC was feasible, effective and safe in a real‐life scenario. Our results were comparable to the phase 3 clinical trial results (TOPAZ‐1). Reduced efficacy was noted in patients with GB‐CA and/ora reduced performance status that warrants further investigation.  \nKEYWORDS  \nbiliary tract cancers, check‐point inhibition, cholangiocarcinoma, cisplatin, durvalumab, gemcitabine, immuno‐chemotherapy, programmed death‐ligand 1 inhibitor  \nINTRODUCTION  \nBiliary tract cancer (BTC) represents the second‐most common primary liver cancer. BTCs comprise a highly heterogenous group of tumors that are classified by anatomic localization into intrahepatic cholangiocarcinoma (iCCA), extrahepat","cbCaiq5RZgAzPyOj","https://ap.wps.com/l/cbCaiq5RZgAzPyOj","pdf",696172,13,"English","# Abstract\n# Background\n# Objective\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What treatment regimen was assessed for biliary tract cancer in this study?\",\"answer\":\"The study evaluated immune-chemotherapy combining gemcitabine, cisplatin, and the PD-L1 inhibitor durvalumab (GCD).\"},{\"question\":\"How were efficacy and safety outcomes analyzed?\",\"answer\":\"Patients treated with GCD from 9 German centers were included, with overall survival, response rate, and adverse events analyzed retrospectively using Kaplan–Meier analyses and Cox regression.\"},{\"question\":\"What patient-related factors were associated with overall survival?\",\"answer\":\"Univariate analysis linked overall survival with age ≥70, ECOG performance status ≥1, status post cholecystectomy, gall bladder cancer status, and higher baseline CRP; GB-CA and ECOG PS ≥1 remained independent in multivariable Cox regression.\"}]","Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort | PDF",1790017501,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf5453681881d1a066f2cc5c0e503f19.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91399a19865acb338891f4e479506bed.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bbc89159c290a6e6de93c6ed8bf81bd0.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7aba5ef1ebb072d29ecb710f502f5a5f.webp",980,1287]